Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): Rationale and Study Design

Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
Hypertension Research (Impact Factor: 2.94). 09/2006; 29(9):703-9. DOI: 10.1291/hypres.29.703
Source: PubMed

ABSTRACT Diabetic nephropathy (DN) is a leading cause of endstage renal disease (ESRD) in Japan and Hong Kong. Asian patients are known to be more predisposed to DN and ESRD than Caucasians. Strict blood glucose and blood pressure control are key factors in prevention and treatment of DN. In the last decade, inhibition of the renin-angiotensin-aldosterone (RAA) system has been confirmed to reduce the incidence of cardiovascular complications in Caucasian patients with diabetes. Although the RENAAL study has demonstrated the beneficial effects of inhibition of the RAA system on prevention of ESRD and death in type 2 diabetic patients with overt proteinuria, only 17% of patients in this multicenter study were of Asian ethnicity. Given the predilection of Asian diabetic patients for renal complications and the rising burden of ESRD, there is a need to confirm these findings in a homogenous group of Asian patients. The ORIENT (Omesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial) is a randomized, double-blind, placebo-controlled study in Japan and Hong Kong to evaluate the renal protective benefits of olmesartan medoxomil in type 2 diabetic patients with overt proteinuria (urinary albumin to creatinine ratio > or =300 mg/g creatinine) and renal insufficiency (serum creatinine: 1.0-2.5 mg/dl). The study has a targeted enrollment of 400 Japanese and Hong Kong Chinese patients. The primary outcome is the composite endpoint of time to the first occurrence of doubling of serum creatinine, ESRD (serum creatinine more than 5.0 mg/dl, the need for chronic dialysis, or renal transplantation) or death. The average follow-up period is 4 years and the study ends in 2009.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic nephropathy is the leading cause of end-stage renal disease and is associated with an increased risk of cardiovascular events. Dietary omega-3 fatty acid (FA) has cardioprotective effect and is associated with a slower deterioration of albumin excretion in patients with diabetic nephropathy. In this study, we evaluated the effect of omega-3 FA on proteinuria in diabetic nephropathy patients who are controlling blood pressure (BP) with angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB). In addition, we identified changes in erythrocyte membrane FA contents. A total of 19 patients who were treated with ACEi or ARB for at least 6 months were treated for 12 weeks with omega-3 FA (Omacor, 3 g/day) or a control treatment (olive oil, 3 g/day). Proteinuria levels were unchanged after 12 weeks compared with baseline values in both groups. The erythrocyte membrane contents of omega-3 FA and eicosapentaenoic acid (EPA) were significantly increased, and oleic acid, arachidonic acid : EPA ratio, and omega-6 : omega-3 FA ratio were significantly decreased after 12 weeks compared with the baseline values in the omega-3 FA group. Although omega-3 FA did not appear to alter proteinuria, erythrocyte membrane FA contents, including oleic acid, were altered by omega-3 FA supplementation.
    International Journal of Endocrinology 01/2015; 2015:1-8. DOI:10.1155/2015/208121 · 1.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Arterial calcification is an active process resulting from the interaction of factors that both promote and inhibit the process. Interaction of these factors results in phenotype transdifferentiation of vacular smooth muscle cells and pericytes into osteoblast-like cells. In addition to this active process, oversaturation of extracellular fluid with high serum calcium and phosphate contributes to calcium apatite precipitation. Arterial calcifications exist in two frequently interrelated types: intimal and medial. Intimal calcification is a part of advanced atherosclerosis and results in plaque development, arterial lumen decrease or occlusion, and ischemic lesions downstream. Medial calcifications result in the stiffening of arterial walls, with increased systolic and decreased diastolic pressures, resulting in cardiac pressure overload, left-ventricular hypertrophy, and decreased myocardial perfusion. Both types are associated with increased cardiovascular morbidity and mortality.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and end-stage renal disease (ESRD). Patients with diabetic nephropathy have a high burden of cardiovascular morbidity and mortality. Therefore, interventions that reduce the incidence and progression rate of DN will reduce morbidity and mortality rates as well as health care costs. Hyperglycemia and arterial hypertension are the two main risk factors for DN, but even in the presence of hyperglycemia and elevated blood pressure (BP) for long periods, DN develops only in susceptible patients. Family studies have confirmed the presence of hereditary factors in the development of DN. Besides these four key factors, others have also been implicated, although their impact is less relevant. A systematic approach aiming at prompt diagnosis and intervention can reduce the incidence of DN and slow progression toward ESRD


Available from